<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antiviral, antiproliferative and immunomodulating effect of interferon alpha (INF alpha) has led to its widespread use in malignant diseases </plain></SENT>
<SENT sid="1" pm="."><plain>In hematology, the clinical effect of INF alpha has been proven empirically for several lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>--hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005526'>lymphoid leukemia</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>--and also for <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath>, particularly <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>However, after 10 years of use, the impact of INF alpha on patient management compared with conventional treatments remains a matter of debate </plain></SENT>
<SENT sid="3" pm="."><plain>Interest in cost-containment and the frequency of adverse effects after long-term treatment also raises many questions </plain></SENT>
<SENT sid="4" pm="."><plain>A critical analysis of the role of INF alpha in each specific indication is thus required </plain></SENT>
</text></document>